AbbVie acquisition signals confidence in small-cap biotech sector’s growth potential

AbbVie Inc (NYSE:ABBV)'s approximately $137.5 million acquisition of Landos Biopharma has sparked interest once again in novel innovations with high-growth prospects in the small-cap biotech sector, according to analysts at Noble Capital.

AbbVie, best known for producing rheumatoid arthritis and Crohn's Disease medication Humira, recently announced the deal to bolster its portfolio of drug candidates for inflammatory and autoimmune diseases.  

Landos Biopharma’s lead clinical asset is NX-13, an oral NLRX1 agonist that is in Phase 2 trials for the treatment of the inflammatory bowel disease ulcerative colitis. 

The deal underscores the allure and value for small-cap investors in emerging biotech firms with promising pipeline candidates, Noble wrote.

"As larger pharmaceutical companies seek to bolster their portfolios and drive innovation, strategic acquisitions of small-cap biotechs with compelling assets can provide attractive exit opportunities and significant returns for investors," analysts wrote.

"With the rising interest in novel therapies for inflammatory and autoimmune diseases, the AbbVie-Landos deal serves as a reminder of the potential value that can be unlocked in the small-cap biotech realm. As larger players seek to fortify their pipelines, the spotlight on promising small-cap innovators is likely to intensify, presenting exciting opportunities for investors in this space."

Acquiring small-cap biotech companies offers major pharmaceutical players the ability to expand and diversify their product portfolios with compelling assets while offering an attractive exit avenue and returns for investors.

To drive innovation and remain competitive, there is growing interest in emerging biotech firms, especially those targeting inflammatory and autoimmune diseases.

Among them is Immunic Inc (NASDAQ:IMUX), a New York City-headquartered biotech developing a pipeline of oral, small molecule therapies for chronic inflammatory and autoimmune diseases.

Its lead asset vidofludimus calcium (IMU-838) is currently in Phase 2 and Phase 3 clinical trials for the treatment of relapsing and progressive multiple sclerosis (MS).

Preclinical data has demonstrated that IMU-838 has neuroprotective, anti-inflammatory and anti-viral effects, in addition to having an attractive and consistent pharmacokinetic, safety and tolerability profile.

It acts as an activator of Nurr1, a nuclear receptor involved in the protection of neurons from cell death, which Immunic believes means the drug could target progression independent of relapse activity, the event responsible for irreversible disability accumulation in patients with relapsing MS.

Meanwhile, Tiziana Life Sciences Ltd (NASDAQ:TLSA) is developing alternative routes of immunotherapy, such as nasal, oral and inhalation administrations, to target neurodegenerative and lung diseases.

Its pipeline includes assets targeting Secondary Progressive MS, Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease, and Crohn's Disease, among other indications. The company’s lead drug asset is intranasal foralumab, an anti-CD3 monoclonal antibody.

Other news from across the small-cap biotech sector:

• atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has dosed the first patient in its Phase 1b trial evaluating its proprietary oral form of DMT (VLS-01) in patients with treatment-resistant depression. The study was designed to evaluate the relative safety, tolerability, pharmacokinetics and pharmacodynamics of VLS-01 compared to intravenous DMT, with topline results expected in the second half of 2024.  
• Atossa Therapeutics Inc (NASDAQ:ATOS) announced that a pre-menopausal breast cancer patient has completed a five-year treatment using its investigational drug (Z)-endoxifen. The company said that the patient, who was diagnosed with Estrogen Receptor positive (ER+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer, remains cancer-free with no significant safety or tolerability issues reported throughout the treatment period.  
• BioVie Inc (NASDAQ:BIVI) told shareholders that through a recently completed financing, it has secured the funds required to advance its lead asset NE3107 for Parkinson’s Disease. It is finalizing a Phase 2b trial of NE3107 as a first-line monotherapy for Parkinson’s Disease, which it aims to launch in late summer of 2024.
• Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced that it has completed patient enrollment in its Phase 2 study investigating its anti-inflammatory therapy CardiolRx for patients with recurrent pericarditis, being inflammation of the thin, fluid-covered sac that covers the heart. Topline results are expected in the second quarter of 2024 and will guide the design of a Phase 3 trial, a necessary step for potential regulatory approval.  
• Filament Health Corp (NEO:FH, OTCQB:FLHLF) announced that it has shipped its botanical psilocybin drug candidate PEX010 to researchers in the United States, Canada, Belgium and Israel to be used in clinical trials for a range of mental health indications. It said PEX010 is authorized for investigation in 30 clinical trials globally targeting 13 indications.
• Medicus Pharma (TSX-V:MDCX) told investors that it has received feedback from the US Food and Drug Administration (FDA) on its Phase 2 clinical protocol to non-invasively treat basal cell carcinoma, a skin cancer, with its microneedle technology. It plans to make a full submission to the FDA during the second quarter of 2024 to provide information requested by the agency.
• OKYO Pharma Ltd (NASDAQ:OKYO) unveiled results from a Phase 2 study that showed its lead drug candidate OK-101 induced significant and measurable improvement in various indications and symptoms associated with dry eye disease. Notably, this included reducing ocular pain.
• Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) said it will host advisory board meetings at two upcoming urologic community forums to present data from its Phase 2 bladder cancer study. It said that the interim clinical data details the safety and efficacy of Ruvidar-based photodynamic therapy for the treatment of Bacillus Calmette Guerin-unresponsive non-muscle invasive bladder cancer carcinoma in-situ.